Search for a command to run...
ResMed Inc.
Medical Instruments & Supplies
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Sep 11, 2026 | Rohit KhannaD | Stock | Sell |
| $1,001 - $15,000 |
| $218.27 |
| $230.05 |
| +5.4% |
| +3.3% |
Aug 3, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $214.57 | $230.87 | +7.6% | +6.6% |
May 27, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $205.51 | $199.72 | -2.8% | -0.2% |
May 15, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $200.75 | $193.69 | -3.5% | -3.9% |
May 1, 2026 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $203.83 | $190.02 | -6.8% | -11.7% |
Apr 13, 2026 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $228.92 | $201.19 | -12.1% | -20.3% |
Mar 30, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $218.75 | $210.70 | -3.7% | -16.3% |
Mar 23, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $226.64 | $220.75 | -2.6% | -11.1% |
Feb 24, 2026 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $250.17 | $221.21 | -11.6% | -5.7% |
Jan 29, 2026 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $256.25 | $255.50 | -0.3% | +0.9% |
Jun 4, 2025 | Kelly Louise MorrisonD | Stock | Sell | $1,001 - $15,000 | $247.52 | $254.47 | +2.8% | -2.4% |
May 28, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $242.39 | $252.69 | +4.2% | -0.7% |
Apr 28, 2025 | Kelly Louise MorrisonD | Stock | Sell | $1,001 - $15,000 | $232.06 | $243.11 | +4.8% | -1.9% |
Apr 23, 2025 | Rohit KhannaD | Stock | Sell | $1,001 - $15,000 | $212.53 | $241.20 | +13.5% | +5.3% |
Mar 6, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $223.03 | $203.34 | -8.8% | +2.7% |
Jan 17, 2025 | Rohit KhannaD | Stock | Buy | $1,001 - $15,000 | $237.66 | $231.44 | -2.6% | -4.6% |
Jan 13, 2025 | Rob BresnahanR | Stock | Sell | $1,001 - $15,000 | $228.23 | $234.51 | +2.8% | -1.0% |
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
This Analyst Just Upgraded ResMed Stock. Here's Why.
RBC Capital Upgrades ResMed to Outperform from Sector Perform
Is Margin Pressure From Rising Costs Altering The Investment Case For ResMed (RMD)?
ResMed Projected to Attain High-Single-Digit EPS Growth in Next Three Years, RBC Says